TransEnterix (NYSE:TRXC) shares jumped today after the medical device company said it sold its first Senhance robot-assisted surgery platform in the U.S., exactly a month after winning FDA clearance.
The sale, to Florida Hospital in Orlando, follows another sale in Taiwan made during the third quarter, president & CEO Todd Pope said during a conference call with analysts last week.
Get the full story at our sister site, The Robot Report.
The post TransEnterix logs first U.S. sale, meets Q3 earnings expecations appeared first on MassDevice.
from MassDevice http://ift.tt/2zymRN9
Cap comentari:
Publica un comentari a l'entrada